LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
2
Historical Outcomes with Cetuximab and Taxanes
3
Tab-Cel BLA Resubmitted to FDA for EBV-Positive PTLD
4
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
5